Literature DB >> 26661503

Therapeutic potential of nicotinamide adenine dinucleotide for nonalcoholic fatty liver disease.

Philippe Gual1,2, Catherine Postic3,4,5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26661503     DOI： 10.1002/hep.28383

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.425


× No keyword cloud information.
  4 in total

1.  Nicotinamide Phosphoribosyltransferase Knockdown Leads to Lipid Accumulation in HepG2 Cells through The SIRT1-AMPK Pathway.

Authors:  Davod Ilbeigi; Mitra Nourbakhsh; Parvin Pasalar; Reza Meshkani; Hajar Shokri Afra; G Hodratollah Panahi; Mohammad Borji; Roya Sharifi
Journal:  Cell J       Date:  2020-07-18       Impact factor: 2.479

Review 2.  Metabolic aspects in NAFLD, NASH and hepatocellular carcinoma: the role of PGC1 coactivators.

Authors:  Elena Piccinin; Gaetano Villani; Antonio Moschetta
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-03       Impact factor: 46.802

3.  Nicotinamide supplementation in diabetic nonalcoholic fatty liver disease patients: randomized controlled trial.

Authors:  Rasha R El-Kady; Amani K Ali; Lamia M El Wakeel; Nagwa A Sabri; May A Shawki
Journal:  Ther Adv Chronic Dis       Date:  2022-02-23       Impact factor: 5.091

4.  Silibinin Restores NAD⁺ Levels and Induces the SIRT1/AMPK Pathway in Non-Alcoholic Fatty Liver.

Authors:  Federico Salomone; Ignazio Barbagallo; Justyna Godos; Vincenzo Lembo; Walter Currenti; Diana Cinà; Roberto Avola; Nicolantonio D'Orazio; Filomena Morisco; Fabio Galvano; Giovanni Li Volti
Journal:  Nutrients       Date:  2017-09-30       Impact factor: 5.717
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.